Antithrombogenic effects of topically applied tissue factor pathway inhibitor (TFPI) in a rabbit model of traumatized arterial autografts: A preliminary report

Kumamoto Medical Journal

Volumn 46, Issue 1, 1998, Pages 7-11

  Sun, Ling Bo ^a   Goto, Hiraaki ^a   Utoh, Junichi ^a   Tsurusaki, Shigeyuki ^a   Hamuro, Tsutomu ^b   Kamikubo, Yu ichi ^b   Kitamura, Nobuo ^b  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY GRAFT; ARTICLE; BLOOD CLOTTING; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL SURGERY; FEMORAL ARTERY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RABBIT; STATISTICAL ANALYSIS; THROMBOGENESIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031827470     PISSN: 00235326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wilcox, J. N., Smith, K. M., Schwartz, S. M. and Gordon, D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA. 86, 2839-2843, 1989.
2. Thomas, L. Studies on the intravascular thromboplastin effect of tissue suspensions in mice: II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull. Johns Hopkins Hosp. 81, 26-42, 1947.
3. Schneider, C. L. The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am. J. Physiol. 149, 123-129, 1947.
4. Hjort, P. F. Intermediate reactions in the coagulation inhibitor of blood with tissue thromboplastin. Scand. J. Clin. Lab. Invest. 9, 173-182, 1957.
5. Rao, L. V. and Rapaport, S. I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69, 645-651, 1987.
6. Broze, G. J. Jr., Warren, L. A., Novotny, W. F., Higuchi, D. A., Girard, J. J. and Miletich, J. P. The lipoprotein-associated coagulation inhibitor that inhibits factor VII-tissue factor complex also inhibits Xa: insight into its possible mechanism of action. Blood 71, 335-343, 1988.
7. Nordfang, O., Bjorn, S. E., Valentin, S., Nielsen, L. S., Wildgoose, P., Beck, T. C. and Hedner, U. The c-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 30, 10371-10376, 1991.
8. Broze, G. J. Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu. Rev. Med. 46, 103-112, 1995.
9. Broze, G. J. Jr. and Miletich, J. P. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc. Natl. Acad. Sci. USA 84, 1886-1890, 1987.
10. Wun, T-C., Kretzmer, K. K., Girard, T. J., Miletich, J. P. and Broze, G. J. Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J. Biol. Chem. 263, 6001-6004, 1988.
11. Das, S. K. and Miller, J. H. Current status of topical antithrombotic agents in microvascular surgery [review]. Microsurgery 15, 630-632, 1994.
12. Cooley, B. C. and Gould, J. S. Topically applied antithrombotic agents offer a new therapeutic approach to the prevention of microvascular thrombosis. Microsurgery 12, 281-287, 1991.
13. Bowman, W. C. and Rand, M. J. Textbook of Pharmacology. 2nd edition, chapter 21.15-21.16, Blackwell Scientific Publications, London, 1984.
14. Khouri, R. K., Koudi, B., Kaiding, F., Ornberg, R. L. and Wun, T-C. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann. Plast. Surg. 30, 398-404, 1993.
15. Ozbeck, M. R., Brown, D. M., Deune, E. G., Lantieri, L. A., Kania, N. M., Pasia, E. N., Cooly, B.C., Wun, T-C. and Khouri, R.K. Topic tissue factor pathway inhibitor improves free-flap survival in a model simulating free-flap errors. J. Reconstr. Microsurg. 11, 185-188, 1995.
16. 1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb. Haemost 71, 214-219, 1994.
17. Nakashima, H., Teramoto, K., Yagi, M., Mamuro, T. and Kamikubo, Y. Experience of tissue factor pathway inhibitor (TFPI). The 21st Annual Meeting of Japan Society of Reconstructive Microsurgery (abstract in Japanese) pp. 87, 1994.
18. Enjyoji, K., Miyata, T., Kamikubo, Y. and Kato, H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: A segment, Gly212- Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 34, 5725-5735, 1995.
19. Cooley, B. C. and Hansen, F. C. Microvascular repair following local crush and avulsion vascular injury. Microsurgery 6, 46-48, 1985.
20. Ornberg, R. L., Deune, E. G., Ozbeck, M. R., Wun, T-C. and Khouri, R. K. Localization of topically applied TFPI binding sites in an intimectomized microvessel. Thromb. Haemost. 73, 55-58, 1995.
21. Hiebert, L. M., Wice, S. M., McDuffie, N. M. and Jagues, L. B. The heparin target organ - the endothelium. Studies in a rat model. Q. J. M. 86, 341-348, 1993.
22. Khouri, R. K. Avoiding free flap failure [review]. Clin. Plast. Surg. 19, 773-781, 1992.
23. Schmitz, R., Kansy, M., Moser, K. H. and Treckmann, J. Effect of low-dose subcutaneous heparin on postoperative wound hematomas: randomized clinical trial on hospitalized inguinal hernia patients in Germany. World J. Surg. 19, 416-418, 1995.
24. Isogai, N., Kamiishi, H. and Chichibu, S. Re-endothelialization stages at the microvascular anastomosis. Microsurgery 9, 87-94, 1988.